

HBRN Adult Immune Active Trial Bibliography

Publications

Feld JJ, Wahed AS, Fried M, Ghany MG, Di Bisceglie AM, Perrillo RP, Khalili M, Yang X, Belle SH, Janssen HLA, Terrault N, Lok AS for the Hepatitis B Research Network (HBRN). [Withdrawal of Long-Term Nucleotide Analogue Therapy in Chronic Hepatitis B: Outcomes from the Withdrawal Phase of the HBRN Immune Active Treatment Trial](#). *Am J Gastroenterol*. 2023 Jan 13. doi: 10.14309/ajg.0000000000002176. Online ahead of print. PMID: 36728214.

Ghany MG, Belle SH, Kleiner DE, Smith C, Kelley SS, Rosenthal P, Fontana RJ for the Hepatitis B Research Network. [Safety and Yield of Percutaneous Liver Biopsy in Adults and Children with Chronic Hepatitis B: Results from a Prospective, Multicenter Study](#). *Hepatol Commun*. 2023;7:e0116. doi: 10.1097/HC9.000000000000116. PMCID: PMC10187861.

Kleiner DE, Lisker-Melman M, Wahed AS, Bhan AK, Nalesnik MA, Choi EK, Leonard KK, Ghany MG, Chung RT, Di Bisceglie AM for the HBRN. [Immunohistochemical Staining for Hepatitis B Viral Antigens in Liver Biopsies and Association with Clinical, Biochemical, and Virologic Features of Disease](#). *J Gastroenterol Hepatol*. 2023 Mar 8. doi: 10.1111/jgh.16167. Online ahead of print. PMID: 36890337.

Terrault NA, Lok AS, Wahed AS, Ghany MG, Perrillo RP, Fried MW, Wong DK, Khalili M, Lau DTY, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper SL, Chung RT, Patel K, Roberts LR, Belle SH, Janssen HLA for the Hepatitis B Research Network. [Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B](#). *Am J Gastroenterol*. 2023 Jan 5. doi: 10.14309/ajg.0000000000002125. Online ahead of print. PMID: 36599136.

In addition, the HBRN has had the following presentations at national and international meetings

American Association for the Study of Liver Diseases (AASLD)

AASLD 2020

Terrault N, Lok AS, Wahed AS, Wong DKH, Khalili M, Fried MW, Lau D, Ghany MG, Sterling RK, Di Bisceglie AM, Perrillo RP, Lisker-Melman M, Cooper S, Chung RT, Patel K, Roberts LR, Landis C, Hassan MA, Aoki CA, Belle S, Janssen HLA. **Randomized Trial of 192 Weeks of Tenofovir With or Without Peginterferon Alfa for the First 24 Weeks Followed by Protocolized Withdrawal in Adults with Chronic Hepatitis B**. *Hepatology* 2020; 72 (Suppl. 1):15A-16A.

AASLD 2021

Evon DM, Lin HS, Wahed A, Khalili M, Fontana RJ, Hoofnagle JH. **Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial**. *Hepatology* 2021; 74 (Suppl. 1):498A.

Feld JJ, Wahed A, Ghany MG, Khalili M, Terrault N, Perrillo RP, Di Bisceglie AM, Fried MW, Belle S, Janssen HLA, Lok AS. **Treatment Withdrawal After Long-Term Nucleotide Analogue Therapy With or Without Peginterferon: Predictors of ALT Flares, HBsAg Decline, and Active Disease**. *Hepatology* 2021; 74 (Suppl. 1):501A-502A.

Perrillo R, Lok AS, Leonard K, Ghany M, Terrault N, Belle SH, Janssen HLA. **The Relationship Between ALT Flares and HBV Antigen Kinetics During Treatment with Tenofovir (TDF) Monotherapy vs. Peginterferon (PEGIFN) Plus TDF**. *Hepatology* 2021; 74 (Suppl. 1):501A.

Terrault N, Lok AS, Wahed A, Ghany MG, Perrillo RP, Fried MW, Wong DKH, Khalili M, Lau D, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper S, Chung RT, Patel K, Roberts LR, Landis C, Aoki CA, Hassan MA, Belle S, Hoofnagle JH, Janssen HLA. **Effects of HBV Subgenotype A2 and an Initial 24-week Course of Peginterferon on Outcomes with Longer-Term Tenofovir: The Multicenter HBRN Immune Active (IA) Trial**. *Hepatology* 2021; 74 (Suppl. 1):479A.